Double-Blind Crossover Clinical and Pharmacokinetic Comparison of Oral Morphine Syrup and Sustained Release Morphine Sulfate Capsules in Patients with Cancer-Related ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1997-06

AUTHORS

Jean-François Gillette, Christophe Ferme, Nancy Moisy, Laurent Mignot, Roger Schach, Jean-René Vignaux, Jean G. Besner, Gilles Caille, Dominique Belpomme

ABSTRACT

A total of 35 patients with advanced cancer and severe pain not controllable by step 2 analgesics (according to WHO criteria) were included in this double-blind study. No patients were receiving concomitant oncological treatment. During a stabilisation period, all patients received sufficient morphine sulfate 5 mg/ml syrup every 4 hours to achieve a satisfactory level of pain relief (60 to 300 mg/day). The patients were then randomised to receive the same dosage of morphine sulfate 5 mg/ml syrup every 4 hours or sustained release (SR) morphine sulfate (as 30 or 60mg capsules) every 12 hours for 6 days, according to a double-blind crossover design. Analgesic efficacy was assessed daily with a visual analogue scale and a 5-point verbal rating scale. At the end of each treatment period, morphine plasma concentrations at steady-state were measured by high performance liquid chromatography. There were no differences between the 2 formulations in terms of subjective analgesic efficacy (measured at 10am, 2pm, 6pm and 10pm) among 20 evaluable patients. Overall, the incidence of opiate-related adverse events was similar with both formulations, and no unexpected adverse events were reported. Mean (± SD) pharmacokinetic parameters assessed in 25 patients were as follows: the maximum plasma concentration was 49.5 ± 28.4 µg/L for morphine syrup vs 48.1 ± 30.7 for the SR capsules [90% confidence interval (CI) 86.8 to 114.0%]; and the area under the concentration-time curve from zero to 12 hours (AUC12h) was 308.4 ± 203.8 µg/L·h for the syrup vs 323 ± 201.7 for the capsules (90% CI 99.1 to 124.5%). There was a linear relationship between the daily dose of morphine and AUC12h. The results of this study suggest that equal dosages of morphine as SR capsules (containing 30 or 60mg morphine) given 12-hourly and morphine 5 mg/ml syrup given 4-hourly are bioequivalent. Furthermore, the 2 formulations are equally effective and well tolerated in the treatment of severe pain in patients with cancer. More... »

PAGES

22-27

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00044011-199700141-00006

DOI

http://dx.doi.org/10.2165/00044011-199700141-00006

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1026940420


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Ren\u00e9 Huguenin", 
          "id": "https://www.grid.ac/institutes/grid.418205.a", 
          "name": [
            "Service de R\u00e9animation, Centre Ren\u00e9 Huguenin, 35, rue Dailly, 92210, Saint-Cloud, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gillette", 
        "givenName": "Jean-Fran\u00e7ois", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "D\u00e9partement M\u00e9dicine Interne Oncologie, CMC de Bligny, Briis sous Forges, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ferme", 
        "givenName": "Christophe", 
        "id": "sg:person.0616444032.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616444032.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Bichat-Claude-Bernard", 
          "id": "https://www.grid.ac/institutes/grid.411119.d", 
          "name": [
            "Service Chirurgie ORL et Cervico-Faciale, H\u00f4pital Bichat, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moisy", 
        "givenName": "Nancy", 
        "id": "sg:person.01246734007.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246734007.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Foch", 
          "id": "https://www.grid.ac/institutes/grid.414106.6", 
          "name": [
            "D\u00e9partement Onco-H\u00e9matologie, H\u00f4pital Foch, Suresnes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mignot", 
        "givenName": "Laurent", 
        "id": "sg:person.0651522641.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651522641.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "UniCancer Group", 
          "id": "https://www.grid.ac/institutes/grid.418189.d", 
          "name": [
            "Service de R\u00e9animation, Centre Paul Strauss, Strasbourg, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schach", 
        "givenName": "Roger", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Claudius Regaud", 
          "id": "https://www.grid.ac/institutes/grid.417829.1", 
          "name": [
            "Centre Claudius R\u00e9gaud, Toulouse, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vignaux", 
        "givenName": "Jean-Ren\u00e9", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Facult\u00e9 de Pharmacie, Montr\u00e9al, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Besner", 
        "givenName": "Jean G.", 
        "id": "sg:person.01222514271.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222514271.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Facult\u00e9 de Pharmacie, Montr\u00e9al, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Caille", 
        "givenName": "Gilles", 
        "id": "sg:person.01030164745.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030164745.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "ARTAC, Boulogne, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Belpomme", 
        "givenName": "Dominique", 
        "id": "sg:person.0114056145.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0114056145.09"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/j.1365-2044.1987.tb04107.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017740864"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/j.1552-4604.1995.tb04106.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023546338"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-199651050-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032095988", 
          "https://doi.org/10.2165/00003495-199651050-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19890601)63:11<2275::aid-cncr2820631136>3.0.co;2-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037356147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00044011-199700141-00009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042774814", 
          "https://doi.org/10.2165/00044011-199700141-00009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2044.1989.tb09143.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043233527"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00609900", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046038572", 
          "https://doi.org/10.1007/bf00609900"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00609900", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046038572", 
          "https://doi.org/10.1007/bf00609900"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00609900", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046038572", 
          "https://doi.org/10.1007/bf00609900"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1987.5.6.956", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079835742"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081404264", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082463999", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1997-06", 
    "datePublishedReg": "1997-06-01", 
    "description": "A total of 35 patients with advanced cancer and severe pain not controllable by step 2 analgesics (according to WHO criteria) were included in this double-blind study. No patients were receiving concomitant oncological treatment. During a stabilisation period, all patients received sufficient morphine sulfate 5 mg/ml syrup every 4 hours to achieve a satisfactory level of pain relief (60 to 300 mg/day). The patients were then randomised to receive the same dosage of morphine sulfate 5 mg/ml syrup every 4 hours or sustained release (SR) morphine sulfate (as 30 or 60mg capsules) every 12 hours for 6 days, according to a double-blind crossover design. Analgesic efficacy was assessed daily with a visual analogue scale and a 5-point verbal rating scale. At the end of each treatment period, morphine plasma concentrations at steady-state were measured by high performance liquid chromatography. There were no differences between the 2 formulations in terms of subjective analgesic efficacy (measured at 10am, 2pm, 6pm and 10pm) among 20 evaluable patients. Overall, the incidence of opiate-related adverse events was similar with both formulations, and no unexpected adverse events were reported. Mean (\u00b1 SD) pharmacokinetic parameters assessed in 25 patients were as follows: the maximum plasma concentration was 49.5 \u00b1 28.4 \u00b5g/L for morphine syrup vs 48.1 \u00b1 30.7 for the SR capsules [90% confidence interval (CI) 86.8 to 114.0%]; and the area under the concentration-time curve from zero to 12 hours (AUC12h) was 308.4 \u00b1 203.8 \u00b5g/L\u00b7h for the syrup vs 323 \u00b1 201.7 for the capsules (90% CI 99.1 to 124.5%). There was a linear relationship between the daily dose of morphine and AUC12h. The results of this study suggest that equal dosages of morphine as SR capsules (containing 30 or 60mg morphine) given 12-hourly and morphine 5 mg/ml syrup given 4-hourly are bioequivalent. Furthermore, the 2 formulations are equally effective and well tolerated in the treatment of severe pain in patients with cancer.", 
    "genre": "research_article", 
    "id": "sg:pub.10.2165/00044011-199700141-00006", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100199", 
        "issn": [
          "1173-2563", 
          "1179-1918"
        ], 
        "name": "Clinical Drug Investigation", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "name": "Double-Blind Crossover Clinical and Pharmacokinetic Comparison of Oral Morphine Syrup and Sustained Release Morphine Sulfate Capsules in Patients with Cancer-Related Pain", 
    "pagination": "22-27", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "80567cf7ba72700f8654d5fb3f1b7959040b469ccb601213499e0ad5f97b168c"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00044011-199700141-00006"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1026940420"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00044011-199700141-00006", 
      "https://app.dimensions.ai/details/publication/pub.1026940420"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T16:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8669_00000505.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.2165/00044011-199700141-00006"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00044011-199700141-00006'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00044011-199700141-00006'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00044011-199700141-00006'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00044011-199700141-00006'


 

This table displays all metadata directly associated to this object as RDF triples.

165 TRIPLES      21 PREDICATES      37 URIs      19 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00044011-199700141-00006 schema:about anzsrc-for:11
2 anzsrc-for:1115
3 schema:author N5cd6605521444323a3d89fb79971abdc
4 schema:citation sg:pub.10.1007/bf00609900
5 sg:pub.10.2165/00003495-199651050-00002
6 sg:pub.10.2165/00044011-199700141-00009
7 https://app.dimensions.ai/details/publication/pub.1081404264
8 https://app.dimensions.ai/details/publication/pub.1082463999
9 https://doi.org/10.1002/1097-0142(19890601)63:11<2275::aid-cncr2820631136>3.0.co;2-4
10 https://doi.org/10.1002/j.1552-4604.1995.tb04106.x
11 https://doi.org/10.1111/j.1365-2044.1987.tb04107.x
12 https://doi.org/10.1111/j.1365-2044.1989.tb09143.x
13 https://doi.org/10.1200/jco.1987.5.6.956
14 schema:datePublished 1997-06
15 schema:datePublishedReg 1997-06-01
16 schema:description A total of 35 patients with advanced cancer and severe pain not controllable by step 2 analgesics (according to WHO criteria) were included in this double-blind study. No patients were receiving concomitant oncological treatment. During a stabilisation period, all patients received sufficient morphine sulfate 5 mg/ml syrup every 4 hours to achieve a satisfactory level of pain relief (60 to 300 mg/day). The patients were then randomised to receive the same dosage of morphine sulfate 5 mg/ml syrup every 4 hours or sustained release (SR) morphine sulfate (as 30 or 60mg capsules) every 12 hours for 6 days, according to a double-blind crossover design. Analgesic efficacy was assessed daily with a visual analogue scale and a 5-point verbal rating scale. At the end of each treatment period, morphine plasma concentrations at steady-state were measured by high performance liquid chromatography. There were no differences between the 2 formulations in terms of subjective analgesic efficacy (measured at 10am, 2pm, 6pm and 10pm) among 20 evaluable patients. Overall, the incidence of opiate-related adverse events was similar with both formulations, and no unexpected adverse events were reported. Mean (± SD) pharmacokinetic parameters assessed in 25 patients were as follows: the maximum plasma concentration was 49.5 ± 28.4 µg/L for morphine syrup vs 48.1 ± 30.7 for the SR capsules [90% confidence interval (CI) 86.8 to 114.0%]; and the area under the concentration-time curve from zero to 12 hours (AUC12h) was 308.4 ± 203.8 µg/L·h for the syrup vs 323 ± 201.7 for the capsules (90% CI 99.1 to 124.5%). There was a linear relationship between the daily dose of morphine and AUC12h. The results of this study suggest that equal dosages of morphine as SR capsules (containing 30 or 60mg morphine) given 12-hourly and morphine 5 mg/ml syrup given 4-hourly are bioequivalent. Furthermore, the 2 formulations are equally effective and well tolerated in the treatment of severe pain in patients with cancer.
17 schema:genre research_article
18 schema:inLanguage en
19 schema:isAccessibleForFree false
20 schema:isPartOf N24c84859454b4ddb88a507b82a60e2e1
21 N5b1d8355e8284dc1bb17f9da86a9d762
22 sg:journal.1100199
23 schema:name Double-Blind Crossover Clinical and Pharmacokinetic Comparison of Oral Morphine Syrup and Sustained Release Morphine Sulfate Capsules in Patients with Cancer-Related Pain
24 schema:pagination 22-27
25 schema:productId N3135acb894fa4dfba78932ee7233079c
26 N8a218dd09d014c31a59575e8eb5dcb9d
27 Nced7abfa227a4528ba215efcd511f4a5
28 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026940420
29 https://doi.org/10.2165/00044011-199700141-00006
30 schema:sdDatePublished 2019-04-10T16:40
31 schema:sdLicense https://scigraph.springernature.com/explorer/license/
32 schema:sdPublisher N718ca27ce9bd40b0bca83e9d6e020c47
33 schema:url http://link.springer.com/10.2165/00044011-199700141-00006
34 sgo:license sg:explorer/license/
35 sgo:sdDataset articles
36 rdf:type schema:ScholarlyArticle
37 N24c84859454b4ddb88a507b82a60e2e1 schema:issueNumber Suppl 1
38 rdf:type schema:PublicationIssue
39 N2af599c29b4544a1afd53965d331c33c schema:affiliation https://www.grid.ac/institutes/grid.418205.a
40 schema:familyName Gillette
41 schema:givenName Jean-François
42 rdf:type schema:Person
43 N3135acb894fa4dfba78932ee7233079c schema:name readcube_id
44 schema:value 80567cf7ba72700f8654d5fb3f1b7959040b469ccb601213499e0ad5f97b168c
45 rdf:type schema:PropertyValue
46 N4b99e838a393491e8286bb21b10679d1 rdf:first Nf2594aa67fb7479982a9b7fffb9b028a
47 rdf:rest Nac3107b702f646a6ae7b819e3e3e4aa8
48 N51d0115a635d430eaf5f41bb11562829 schema:name ARTAC, Boulogne, France
49 rdf:type schema:Organization
50 N5b1d8355e8284dc1bb17f9da86a9d762 schema:volumeNumber 14
51 rdf:type schema:PublicationVolume
52 N5cd6605521444323a3d89fb79971abdc rdf:first N2af599c29b4544a1afd53965d331c33c
53 rdf:rest Ndca2f9cf6b674714afd34cba644b2936
54 N5ef5d9390bc64710b42c6bc4893e165b schema:name Faculté de Pharmacie, Montréal, Canada
55 rdf:type schema:Organization
56 N718ca27ce9bd40b0bca83e9d6e020c47 schema:name Springer Nature - SN SciGraph project
57 rdf:type schema:Organization
58 N7b04c5e99cc54790a366fb217acaa83d rdf:first sg:person.0114056145.09
59 rdf:rest rdf:nil
60 N8670d64dec3b49e59cf09f7a5940e2eb schema:name Faculté de Pharmacie, Montréal, Canada
61 rdf:type schema:Organization
62 N8a218dd09d014c31a59575e8eb5dcb9d schema:name doi
63 schema:value 10.2165/00044011-199700141-00006
64 rdf:type schema:PropertyValue
65 Nac3107b702f646a6ae7b819e3e3e4aa8 rdf:first Ne9978d042d5d453184476a8fa9821495
66 rdf:rest Nd63cea7298de4c25bb51263d91fe4e66
67 Nb55481b6c67c4e10986106ce92bb240e rdf:first sg:person.0651522641.44
68 rdf:rest N4b99e838a393491e8286bb21b10679d1
69 Nced7abfa227a4528ba215efcd511f4a5 schema:name dimensions_id
70 schema:value pub.1026940420
71 rdf:type schema:PropertyValue
72 Ncf76e77928e24cde9b214ab8e868a909 rdf:first sg:person.01246734007.41
73 rdf:rest Nb55481b6c67c4e10986106ce92bb240e
74 Nd63cea7298de4c25bb51263d91fe4e66 rdf:first sg:person.01222514271.17
75 rdf:rest Ne954fccdadbf41daa8897c106bac38ab
76 Ndca2f9cf6b674714afd34cba644b2936 rdf:first sg:person.0616444032.03
77 rdf:rest Ncf76e77928e24cde9b214ab8e868a909
78 Ne1159845b06f4d0480b0a9ab8b037e68 schema:name Département Médicine Interne Oncologie, CMC de Bligny, Briis sous Forges, France
79 rdf:type schema:Organization
80 Ne954fccdadbf41daa8897c106bac38ab rdf:first sg:person.01030164745.49
81 rdf:rest N7b04c5e99cc54790a366fb217acaa83d
82 Ne9978d042d5d453184476a8fa9821495 schema:affiliation https://www.grid.ac/institutes/grid.417829.1
83 schema:familyName Vignaux
84 schema:givenName Jean-René
85 rdf:type schema:Person
86 Nf2594aa67fb7479982a9b7fffb9b028a schema:affiliation https://www.grid.ac/institutes/grid.418189.d
87 schema:familyName Schach
88 schema:givenName Roger
89 rdf:type schema:Person
90 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
91 schema:name Medical and Health Sciences
92 rdf:type schema:DefinedTerm
93 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
94 schema:name Pharmacology and Pharmaceutical Sciences
95 rdf:type schema:DefinedTerm
96 sg:journal.1100199 schema:issn 1173-2563
97 1179-1918
98 schema:name Clinical Drug Investigation
99 rdf:type schema:Periodical
100 sg:person.01030164745.49 schema:affiliation N8670d64dec3b49e59cf09f7a5940e2eb
101 schema:familyName Caille
102 schema:givenName Gilles
103 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030164745.49
104 rdf:type schema:Person
105 sg:person.0114056145.09 schema:affiliation N51d0115a635d430eaf5f41bb11562829
106 schema:familyName Belpomme
107 schema:givenName Dominique
108 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0114056145.09
109 rdf:type schema:Person
110 sg:person.01222514271.17 schema:affiliation N5ef5d9390bc64710b42c6bc4893e165b
111 schema:familyName Besner
112 schema:givenName Jean G.
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222514271.17
114 rdf:type schema:Person
115 sg:person.01246734007.41 schema:affiliation https://www.grid.ac/institutes/grid.411119.d
116 schema:familyName Moisy
117 schema:givenName Nancy
118 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246734007.41
119 rdf:type schema:Person
120 sg:person.0616444032.03 schema:affiliation Ne1159845b06f4d0480b0a9ab8b037e68
121 schema:familyName Ferme
122 schema:givenName Christophe
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616444032.03
124 rdf:type schema:Person
125 sg:person.0651522641.44 schema:affiliation https://www.grid.ac/institutes/grid.414106.6
126 schema:familyName Mignot
127 schema:givenName Laurent
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651522641.44
129 rdf:type schema:Person
130 sg:pub.10.1007/bf00609900 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046038572
131 https://doi.org/10.1007/bf00609900
132 rdf:type schema:CreativeWork
133 sg:pub.10.2165/00003495-199651050-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032095988
134 https://doi.org/10.2165/00003495-199651050-00002
135 rdf:type schema:CreativeWork
136 sg:pub.10.2165/00044011-199700141-00009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042774814
137 https://doi.org/10.2165/00044011-199700141-00009
138 rdf:type schema:CreativeWork
139 https://app.dimensions.ai/details/publication/pub.1081404264 schema:CreativeWork
140 https://app.dimensions.ai/details/publication/pub.1082463999 schema:CreativeWork
141 https://doi.org/10.1002/1097-0142(19890601)63:11<2275::aid-cncr2820631136>3.0.co;2-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037356147
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1002/j.1552-4604.1995.tb04106.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1023546338
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1111/j.1365-2044.1987.tb04107.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1017740864
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1111/j.1365-2044.1989.tb09143.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043233527
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1200/jco.1987.5.6.956 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079835742
150 rdf:type schema:CreativeWork
151 https://www.grid.ac/institutes/grid.411119.d schema:alternateName Hôpital Bichat-Claude-Bernard
152 schema:name Service Chirurgie ORL et Cervico-Faciale, Hôpital Bichat, Paris, France
153 rdf:type schema:Organization
154 https://www.grid.ac/institutes/grid.414106.6 schema:alternateName Hôpital Foch
155 schema:name Département Onco-Hématologie, Hôpital Foch, Suresnes, France
156 rdf:type schema:Organization
157 https://www.grid.ac/institutes/grid.417829.1 schema:alternateName Institut Claudius Regaud
158 schema:name Centre Claudius Régaud, Toulouse, France
159 rdf:type schema:Organization
160 https://www.grid.ac/institutes/grid.418189.d schema:alternateName UniCancer Group
161 schema:name Service de Réanimation, Centre Paul Strauss, Strasbourg, France
162 rdf:type schema:Organization
163 https://www.grid.ac/institutes/grid.418205.a schema:alternateName Hôpital René Huguenin
164 schema:name Service de Réanimation, Centre René Huguenin, 35, rue Dailly, 92210, Saint-Cloud, Paris, France
165 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...